The 2020-2021 biotech "bubble" pushed very early-stage companies into public markets prematurely. The subsequent correction, though painful, has been a healthy reset. It has forced the sector back toward a more suitable, long-duration private funding model where companies can mature before facing public market pressures.

Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

The market correctly sees biology's potential but often misunderstands its timeline. Even with AI, biology is fundamentally harder and slower than software. Daniel Fero warns this mismatch in "tempo" expectations leads to over-funding hype cycles while under-funding foundational companies that are simply moving at the pace required for rigorous biological R&D.

While a challenging fundraising market seems negative, it forces startups to operate with discipline. Unlike in frothy markets where companies expand based on hype, the current climate rewards tangible results. This compels a lean structure focused on high-value projects, creating a healthier long-term business model.

The biotech industry recently endured its own "dot-com bust." Post-COVID hype gave way to investor impatience with the sector's fundamental realities: it takes over 10 years and massive capital ($200B/year industry-wide) to get a drug approved, leading to a sharp market correction.

Instead of rushing to the clinic, MRM Health deliberately slowed down for five years to develop its CORAL platform. This end-to-end platform solves strain selection, single-process manufacturing, and delivery upfront, preventing the CMC (Chemistry, Manufacturing, and Controls) issues that plagued earlier microbiome companies.

The bar for pre-seed funding has risen dramatically. With an abundance of startups already generating revenue (e.g., $1M ARR), VCs are choosing these de-risked opportunities over pure idea-stage companies. This "flight to quality" has bifurcated the market, making it extremely difficult for pre-revenue founders to raise.

The life sciences investor base is highly technical, demanding concrete data and a clear path to profitability. This rigor acts as a natural barrier to the kind of narrative-driven, AI-fueled hype seen in other sectors, delaying froth until fundamental catalysts are proven.

The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.